FCM Stock Overview
Engages in the research, development, and production of original and generic pharmaceutical products for human and veterinary use in Italy. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Friulchem S.p.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.73 |
52 Week High | €1.12 |
52 Week Low | €0.72 |
Beta | 0.53 |
11 Month Change | -4.58% |
3 Month Change | -11.52% |
1 Year Change | -31.13% |
33 Year Change | -39.92% |
5 Year Change | -56.80% |
Change since IPO | -58.09% |
Recent News & Updates
Shareholder Returns
FCM | IT Pharmaceuticals | IT Market | |
---|---|---|---|
7D | -5.2% | -3.0% | -0.7% |
1Y | -31.1% | 4.3% | 12.7% |
Return vs Industry: FCM underperformed the Italian Pharmaceuticals industry which returned 3.6% over the past year.
Return vs Market: FCM underperformed the Italian Market which returned 12.7% over the past year.
Price Volatility
FCM volatility | |
---|---|
FCM Average Weekly Movement | 3.7% |
Pharmaceuticals Industry Average Movement | 5.3% |
Market Average Movement | 4.2% |
10% most volatile stocks in IT Market | 7.5% |
10% least volatile stocks in IT Market | 2.4% |
Stable Share Price: FCM has not had significant price volatility in the past 3 months compared to the Italian market.
Volatility Over Time: FCM's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 91 | Disma Mazzola | www.friulchem.com |
Friulchem S.p.A. engages in the research, development, and production of original and generic pharmaceutical products for human and veterinary use in Italy. It offers generic cosmoceuticals and food supplements; and chewable cubes for animals. The company was founded in 1996 and is based in Milan, Italy.
Friulchem S.p.A. Fundamentals Summary
FCM fundamental statistics | |
---|---|
Market cap | €4.38m |
Earnings (TTM) | -€314.36k |
Revenue (TTM) | €30.51m |
0.1x
P/S Ratio-13.9x
P/E RatioIs FCM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
FCM income statement (TTM) | |
---|---|
Revenue | €30.51m |
Cost of Revenue | €23.19m |
Gross Profit | €7.32m |
Other Expenses | €7.63m |
Earnings | -€314.36k |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.052 |
Gross Margin | 23.99% |
Net Profit Margin | -1.03% |
Debt/Equity Ratio | 135.8% |
How did FCM perform over the long term?
See historical performance and comparison